Literature DB >> 11152652

Lipopolysaccharide Induces Mucus Cell Metaplasia in Mouse Lung.

K Yanagihara1, M Seki, P W Cheng.   

Abstract

A murine model of lipopolysaccharide (LPS)-induced airway inflammation and epithelial cell phenotypic change, and the time courses of these events are described. A single intratracheal instillation of Pseudomonas aeruginosa LPS in mice resulted in massive recruitment of neutrophils to the lung 2 d after treatment as assessed by differential cell counts of the inflammatory cells in bronchoalveolar lavage fluid and histologic assessment of hematoxylin and eosin (H&E)-stained lung sections. The LPS-induced neutrophilic inflammation subsided substantially on Day 4 and essentially vanished by Day 7. Airway epithelial mucus cells were not detected by Alcian blue periodic acid-Schiff staining until Day 4 after LPS treatment and became more abundant in number as well as in mucus content on Day 7. The expression of Muc5ac messenger RNA (mRNA) as well as glycoprotein was enhanced on Day 2, peaked on Day 4, and decreased on Day 7, whereas enhanced expression of mucin core 2 beta6 N-acetylglucosaminyltransferase (C2GnT)-M mRNA was not detected until Day 4 and peaked on Day 7. The expression of C2GnT-L mRNA in the lung, a marker for activated leukocytes as well as mucus cells, peaked on Day 2 and remained moderately high until Day 7. C2GnT-L mRNA expression in LPS-treated lung correlated with the presence of neutrophils and the appearance of mucus cells in the airway epithelium. We conclude that mucus cell metaplasia and hyperplasia can be generated in mouse lungs with a single intratracheal instillation of LPS. In addition, C2GnT-M may serve as a marker for mucus cells in mouse lung. This LPS-induced mucus cell metaplasia and hyperplasia model should be useful for the study of Pseudomonas-induced airway mucus hypersecretory diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152652     DOI: 10.1165/ajrcmb.24.1.4122

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  19 in total

Review 1.  Airway mucus: From production to secretion.

Authors:  Olatunji W Williams; Amir Sharafkhaneh; Victor Kim; Burton F Dickey; Christopher M Evans
Journal:  Am J Respir Cell Mol Biol       Date:  2006-01-13       Impact factor: 6.914

2.  Transcriptional suppression of CYP2A13 expression by lipopolysaccharide in cultured human lung cells and the lungs of a CYP2A13-humanized mouse model.

Authors:  Hong Wu; Zhihua Liu; Guoyu Ling; David Lawrence; Xinxin Ding
Journal:  Toxicol Sci       Date:  2013-07-24       Impact factor: 4.849

3.  Mucin O-glycan branching enzymes: structure, function, and gene regulation.

Authors:  Pi-Wan Cheng; Prakash Radhakrishnan
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

4.  Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa.

Authors:  Kazuhiro Oshima; Shigeki Nakamura; Naoki Iwanaga; Koji Takemoto; Taiga Miyazaki; Kastunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno; Koichi Izumikawa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.

Authors:  Jung Soo Suk; Nicholas J Boylan; Kanika Trehan; Benjamin C Tang; Craig S Schneider; Jung-Ming G Lin; Michael P Boyle; Pamela L Zeitlin; Samuel K Lai; Mark J Cooper; Justin Hanes
Journal:  Mol Ther       Date:  2011-08-09       Impact factor: 11.454

6.  Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells.

Authors:  Yoshifumi Imamura; Katsunori Yanagihara; Yohei Mizuta; Masafumi Seki; Hideaki Ohno; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Jun-ichi Kadota; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Nobuko Araki; Koichi Yamada; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

8.  Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice.

Authors:  Shigeki Nakamura; Naoki Iwanaga; Masafumi Seki; Kenji Fukudome; Kazuhiro Oshima; Taiga Miyazaki; Koichi Izumikawa; Katsunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

9.  Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii.

Authors:  Koichi Yamada; Katsunori Yanagihara; Norihito Kaku; Yosuke Harada; Yohei Migiyama; Kentaro Nagaoka; Yoshitomo Morinaga; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Hiroo Hasegawa; Hiroshige Mikamo; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

10.  Toll-like receptor 4 agonistic antibody promotes innate immunity against severe pneumonia induced by coinfection with influenza virus and Streptococcus pneumoniae.

Authors:  Akitaka Tanaka; Shigeki Nakamura; Masafumi Seki; Kenji Fukudome; Naoki Iwanaga; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Katsunori Yanagihara; Shigeru Kohno
Journal:  Clin Vaccine Immunol       Date:  2013-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.